+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report



Pulmonary arterial hypertension in a patient treated with dasatinib: a case report



Journal of Medical Case Reports 11(1): 362



There have been several reports on dasatinib-induced reversible pulmonary hypertension. This is the first reported case in Latvia; the patient did not discontinue the drug after the first adverse effects in the form of pleural effusions, which we speculate led only to partial reversion of the disease. A 67-year-old white man with chronic myelogenous leukemia was treated with the dual Src and BCR-ABL tyrosine kinase inhibitor dasatinib. After treatment with dasatinib he had multiple pleural effusions which were suspected to be caused by congestive heart failure. Later a transthoracic Doppler echocardiography and right-sided heart catheterization revealed severe pulmonary hypertension with pulmonary vascular resistance of 12 Wood units and mean pulmonary artery pressure of 53 mmHg. Computed tomography ruled out a possible pulmonary embolism; laboratory specific tests for human immunodeficiency virus, rheumatoid factor, and anti-nuclear antibodies were negative, and dasatinib-induced pulmonary arterial hypertension was diagnosed. A follow-up right-sided heart catheterization and 6-minute walk test done a month after the discontinuation of dasatinib showed significant improvement: mean pulmonary artery pressure of 34 mmHg and pulmonary vascular resistance of 4 Wood units. Patients should always be closely monitored when using dasatinib for a prolonged time. Dasatinib-induced pulmonary hypertension may be fully reversible after the therapy is suspended, but the key factors involved are still unclear and need to be further studied.

(PDF emailed within 0-6 h: $19.90)

Accession: 065448637

Download citation: RISBibTeXText

PMID: 29287600

DOI: 10.1186/s13256-017-1515-9


Related references

Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib. Herz 38(8): 931-933, 2014

Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report. European Heart Journal. Case Reports 3(1): Ytz025, 2019

Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report. Kardiologiia 57(S4): 53-60, 2018

Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review. Zhonghua Jie He He Hu Xi Za Zhi 39(2): 83-87, 2016

Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review. Zhonghua Xue Ye Xue Za Zhi 35(7): 581-586, 2015

Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17): 2128-2137, 2012

Reversible dasatinib-related pulmonary arterial hypertension in a CML patient. Japanese Journal of Clinical Hematology 57(5): 618-623, 2016

Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy. Case Reports in Cardiology 2018: 3895197, 2018

Effect of arginine vasopressin on systemic and pulmonary arterial pressure in a patient with pulmonary hypertension secondary to pulmonary emphysema: a case report. Ja Clinical Reports 3(1): 1, 2017

A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib. Pulmonary Circulation 7(4): 808-812, 2017

Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension. Internal Medicine 50(20): 2341-2346, 2012

Management of pulmonary arterial hypertension associated with congenital heart disease with specific pulmonary arterial hypertension vasoactive drugs combined with transcatheter closure strategy:a case report. Zhonghua Xin Xue Guan Bing Za Zhi 42(11): 963-964, 2015

A case of a patient with idiopathic pulmonary arterial hypertension treated with lung transplantation: a "bumpy road" to success. Polskie Archiwum Medycyny Wewnetrznej 115(6): 565-571, 2007

Successful pregnancy in a patient with idiopathic pulmonary arterial hypertension. Case report. Orvosi Hetilap 157(15): 593-595, 2016

Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat. Bmc Pulmonary Medicine 16(1): 82, 2017